12:00 AM
 | 
Aug 01, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Centanafadine SR: Phase IIb data

A double-blind, crossover, U.S. Phase IIb trial in 85 adults with ADHD showed that twice-daily 400 mg oral centanafadine SR met the primary endpoint of improving ADHD-RS-IV total score from baseline to...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >